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ABSTRACT
Hypoxic cancer cells exhibit resistance to many therapies. This study compared 
the therapeutic effect of targeting the pH regulatory proteins (CAIX, NHE1 and 
V-ATPase) that permit cancer cells to adapt to hypoxic conditions, using both 2D 
and 3D culture models. Drugs targeting CAIX, NHE1 and V-ATPase exhibited anti-
proliferative effects in MCF-7, MDA-MB-231 and HBL-100 breast cancer cell lines in 2D. 
Protein and gene expression analysis in 2D showed that CAIX was the most hypoxia-
inducible protein of the 3 targets. However, the expression of CAIX differed between 
the 3 cell lines. This difference in CAIX expression in hypoxia was consistent with a 
varying activity of FIH-1 between the cell lines. 3D expression analysis demonstrated 
that both CAIX and NHE1 were up-regulated in the hypoxic areas of multicellular 
tumor spheroids. However, the induction of CAIX expression in hypoxia was again 
cell line dependent. 3D invasion assays conducted with spheroids showed that CAIX 
inhibition significantly reduced the invasion of cells. Finally, the capability of both 
NHE1 and CAIX inhibitors to combine effectively with irradiation was exhibited in 
clonogenic assays. Proteomic-mass-spectrometric analysis indicated that CAIX 
inhibition might be combining with irradiation through stimulating apoptotic cell 
death. Of the three proteins, CAIX represents the target with the most promise for 
the treatment of breast cancer.
INTRODUCTION
The unrestricted development of tumors provides 
momentum for cancer cells to grow and survive in areas 
further away from blood vessels in regions beyond the 
effective diffusion distance of oxygen, leading to oxygen 
deficiency (or hypoxia) in these cells [1]. The tumor 
vasculature is highly irregular and is often unsuccessful 
in rectifying this deficit [2], with an estimated 50% of 
advanced breast cancers containing hypoxic tissue areas 
[3]. Low oxygen levels reduce the ability of cells to obtain 
energy through oxidative phosphorylation and cause an 
increased dependency on glycolysis for the production of 
energy. Increased glucose consumption through glycolysis 
leads to the production of H+ ions which, if not controlled, 
can lead to changes in the internal pH of cancer cells. 
Such changes in intracellular pH (pHi) can potentially 
affect almost all cellular processes [4]. Therefore hypoxic 
cancer cells, which produce large amounts of H+ ions 
through glycolysis, need to be able to control their pHi 
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to a greater extent than normal cells, or even aerobic 
cancer cells, to ensure survival within their hostile tumor 
microenvironment. As such, an adaptive feature of 
hypoxic cancer cells is the overexpression and/or elevated 
activity of a number of pH regulating proteins. These 
proteins include carbonic anhydrase IX (CAIX), Na+-H+ 
exchanger 1 (NHE1) and vacuolar H+-ATPase (V-ATPase) 
[5], as illustrated in Supplementary Figure 1.
Each of these proteins contributes to cellular pH 
homeostasis in different ways. Membrane-permeant CO2 is 
a form in which much acid is removed by tumor cells [6]. 
This involves the key enzyme CAIX, which facilitates CO2 
diffusion from cancer cells by catalyzing the extracellular 
conversion of CO2 into HCO3- and H+, thereby maintaining 
a steeper efflux gradient for CO2 [6]. At the same time, 
CAIX causes a decrease in extracellular pH (pHe) due to 
the production of H+ ions extracellularly. Both NHE1 and 
V-ATPase differ in their method of pH regulation. NHE1 
is extremely sensitive to pHi; when pHi drops below a 
certain level, NHE1 is activated by an internal allosteric 
H+-binding regulatory site, leading to NHE1 extruding one 
proton in exchange for one Na+ ion, thereby alkalinizing 
pHi and acidifying pHe [7]. Finally, V-ATPases are ATP-
dependent H+ transporters that transfer protons using the 
energy released by ATP hydrolysis. They transport H+ 
ions from the cytoplasm to intracellular compartments, or, 
if situated within the plasma membrane, across the cell 
surface into the extracellular space [8, 9].
Activation of the hypoxia inducible factor (HIF) 
family of transcription factors is one of the principle oxygen-
responsive signaling pathways that allows the adaptation of 
cancer cells to hypoxia [2, 10]. Both prolyl hydroxylase 
domain (PHD) proteins and Factor Inhibiting HIF-1 (FIH-1) 
are oxygen sensors that control signaling through HIF [11]. 
PHDs hydroxylate HIF-1α, allowing Von Hippel Lindau 
(VHL) factor to bind, targeting HIF-1α for degradation. 
When oxygen levels decrease, the PHD proteins become 
inactive. Under these conditions, HIF-1α heterodimerises 
with HIF-1β and binds to hypoxic response elements 
(HREs) in target genes, leading to the expression of proteins 
that help hypoxic cancer cells survive [11]. While PHD is 
inactivated in hypoxia, FIH-1 retains its activity in low % 
O2 conditions [12, 13]. FIH-1 catalyzes the hydroxylation 
of the C-terminal transactivation domain (C-TAD) of HIF-
1α, impairing the interaction between C-TAD and the co-
activator proteins p300/CREB binding protein (CBP), 
leading to only partial HIF signaling [11]. FIH-1 can be 
inhibited by either severe hypoxic conditions [12], or 
membrane type-1 matrix metalloproteinase (MMP14) [14], 
a protein present on the plasma membrane of cells. FIH-1 
inhibition through either of these mechanisms leads to p300/
CREB binding to HIF-1α, resulting in full HIF-1 signaling.
It is widely believed that hypoxia and HIF have 
essential roles to play in cancer progression, as evidence 
indicates that altered cancer cell metabolism and HIF-
regulated enzymes, such as CAIX, are crucial in the 
processes of tumor cell invasion and metastasis [15]. 
CAIX, NHE1 and V-ATPase, while contributing to the 
alkaline pHi found in hypoxic cancer cells and enabling 
survival in their hostile environment, also lead to the 
formation of an acidic pHe. This acidosis supports cancer 
cell invasion through the degradation of the extracellular 
matrix (ECM), destabilizing intercellular contacts, and 
increasing the motility of cancer cells [16]. Hypoxic 
cancer cells, in addition to having an augmented capacity 
for invasion, are also more resistant to radiotherapy [17] 
and chemotherapy [1] than their aerobic counterparts, 
thereby contributing to breast cancer mortality [3].
The aberrant regulation of H+ ions, leading to a 
reversed pH gradient in cancer cells and tissues when 
compared with normal cells, is a phenomenon that is 
increasingly considered to be one of the most differential 
hallmarks of cancer [18]. The targeting of proteins 
in cancer cells that are responsible for the initiation/
regulation of the reversed pH gradient may be selective 
for malignancy and could lead to the development of more 
effective and less toxic therapies against cancer, either 
alone through inhibiting invasion and metastasis or by 
augmenting the effects of radiotherapy/chemotherapy. The 
aim of this study was to assess the expression of CAIX, 
NHE1 and V-ATPase in breast cancer cells under differing 
O2 conditions, and to compare the therapeutic effect of 
targeting these proteins in both 2D and 3D breast cancer 
models.
RESULTS
Inhibitors of the pH regulating proteins CAIX, 
NHE1 and V-ATPase reduce the proliferation of 
breast cancer cells
The effect of targeting pH regulator proteins on 
cancer cell proliferation was assessed through SRB 
assays. One of the drugs used, S4, has been shown to 
inhibit the tumor associated carbonic anhydrase IX and 
XII isoforms at low nanomolar levels, while having much 
less activity against the non-tumor associated cytosolic 
carbonic anhydrase isoforms [19]. It has been shown to 
be anti-metastatic against MDA-MB-231 lung metastases 
[19]. DMA (5-(N,N-Dimethyl)amiloride hydrochloride), 
used to target NHE1, and bafilomycin A1, used to inhibit 
V-ATPase, have also been demonstrated to be specific for 
their respective targets [20, 21]. Concentrations of the 
inhibitors found to be effective in previous studies were 
used [22–24]. Each cell line was treated with varying 
concentrations of drug and incubated for 72-120h in either 
20% O2 or 0.5% O2 conditions. The effect of the inhibitors 
was also assessed on chronically hypoxic cells that had 
spent more than 10 weeks in 0.5% O2 before treatment 
(see Supplementary Figure 2). Acute hypoxic cells were 
placed into 0.5% O2 conditions 24h before treatment to 
allow them to adapt to hypoxic conditions, while the 
chronic hypoxic cells remained in 0.5% O2 conditions 
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throughout. The data from these studies were used to 
calculate the IC50 (half maximal inhibitory concentration) 
for growth inhibition in response to all of the inhibitors in 
each of the cell lines (Figure 1).
These results demonstrate that all the inhibitors had 
anti-proliferative effects on the 3 breast cancer cell lines 
studied. The V-ATPase inhibitor bafiloymcin A1 was the 
most effective drug tested, with nanomolar concentrations 
having a large effect on cancer cell number. While hypoxic 
conditions and enhanced glycolysis would be assumed 
to increase the dependency of these cells on regulators 
of pHi, acute hypoxic cancer cells were more resistant 
to the anti-proliferative effects of each of the inhibitors, 
exhibiting raised IC50 values in comparison with the 
same cells in 20% O2. This increased resistance to drug 
treatment in acute hypoxic conditions was especially 
noticeable with the CAIX inhibitor S4, as at many of the 
time points in hypoxia no concentration of drug used (up 
to a concentration of 100 μM) led to a 50% reduction 
in cell number. In chronic hypoxia, MCF-7 and MDA-
MB-231 cells had IC50 values for S4 that were similar 
to those seen in aerobic cells. HBL-100 cells were much 
more resistant to the effects of CAIX inhibition in both 
aerobic and hypoxic conditions compared to the other cell 
lines, with no concentration of S4 tested reducing cell 
number by 50%.
The effect of hypoxia on expression of the target 
pH regulators
Because acute hypoxia increased resistance to 
the anti-proliferative effect of the inhibitors, protein 
expression levels of HIF-1α, HIF-2α, CAIX, NHE1 and 
V-ATPase were examined in MCF-7, MDA-MB-231 and 
HBL-100 cell lines cultured in differing O2 conditions 
for varying periods of time using Western blotting of 
whole cell lysates (Figure 2). All 3 cell lines exhibited 
increases in HIF-1α and HIF-2α expression in 0.5% O2, 
Figure 1: The effects of drugs targeting CAIX, NHE1 and V-ATPase on breast cancer proliferation in differing O2 
conditions. The effects of drugs targeting CAIX (S4), NHE1 (DMA) and V-ATPase (bafilomycin A1) on cancer cell proliferation were 
assessed through sulforhodamine B (SRB) assays. Breast cancer cells were treated with the inhibitors for 72, 96 and 120h in aerobic (20% 
O2) or acute hypoxic (0.5% O2) conditions. The effects of the drugs on the proliferation of chronic hypoxic cells, which were cultured for 
over 10 weeks in 0.5% O2 before treatment, were also evaluated. The tables show IC50 values for each of the inhibitors, the concentration 
of drug required to reduce proliferation by 50%. Graphs present representative data, showing the response of each of the cell lines to 72h 
drug treatment in aerobic, acute hypoxic and chronic hypoxic conditions, with each drug treated value normalized against a control value 
(bars represent SEM). Drug structures were drawn using MarvinSketch version 16.3.12, ChemAxon.
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apart from MCF-7 cells, which did not show any change 
in HIF-2α levels in hypoxic conditions. Expression of 
the HIF-1α inducible gene CAIX varied between the cell 
lines, with MDA-MB-231 and HBL-100 cells expressing 
much larger amounts of CAIX compared to MCF-7 
cells, which only markedly expressed CAIX under more 
chronic hypoxic conditions. NHE1 expression was 
unchanged across the 3 cell lines by the different oxygen 
conditions, with the exception of NHE1 levels observed 
in chronically hypoxic MCF-7 cells. An antibody 
targeting the ATP6V1A subunit of V-ATPase was used 
to assess V-ATPase expression; with this antibody, no 
changes in V-ATPase levels were observed in any of 
the cell lines cultured in the different O2 percentages. 
Figure 2: Target protein expression in varying oxygen concentrations in 2D. Whole-cell lysates of MCF-7, MDA-MB-231 
and HBL-100 cells were obtained to examine the levels of 5 target proteins (HIF-1α, HIF-2α, CAIX, NHE1, V-ATPase) in differing oxygen 
concentrations (20% O2, 7% O2, 2% O2 and 0.5% O2) at varying time points (24, 48 and 72h). Protein levels in cells cultured for 10 weeks 
in 0.5% O2 were also analyzed, as was expression in chronic hypoxic cells that were re-oxygenated for 1/3 weeks before lysate acquisition. 
Experiments looking at expression levels in the 10 week 0.5% O2 and 1/3 week re-ox lysates were conducted separately to the 24/48/72h 
westerns.
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For each of the proteins analyzed, re-oxygenation of the 
chronic hypoxic cells led to target protein expression 
intensities returning to levels that were similar to those 
seen in aerobic cells, suggesting that such changes are 
reversible and non-permanent.
mRNA levels of the pH regulators were also 
assessed in aerobic, acute hypoxic and chronic hypoxic 
conditions. The CAIX mRNA results mirrored those 
of the CAIX protein in the 3 cell lines. There was a 
significant increase in CAIX mRNA levels in the MDA-
MB-231 and HBL-100 cell lines cultured in acute and 
chronic hypoxic conditions (Figure 3A and 3B). MCF-7 
cells in chronic hypoxia also exhibited increased CAIX 
mRNA levels compared to acute hypoxic or aerobic cells; 
this increase, however, was not significant (Figure 3B). 
No significant increases in NHE1 were observed in any 
of the cell lines (Figure 3C), while mRNA levels of the 
V-ATPase ATP6V1A subunit targeted in the westerns 
decreased in hypoxia (Figure 3D). Analysis of 2 other 
V-ATPase subunits, ATP6V0A3 and ATP6V0A4, which 
have been linked to the targeting of V-ATPase to the 
plasma membrane [25], showed that the mRNA levels of 
the ATP6V0A4 subunit significantly increased in hypoxic 
conditions in the MDA-MB-231 cell line (Figure 3E), 
whereas the mRNA levels of the ATP6V0A3 subunit 
stayed constant (Supplementary Figure 3).
Reduced CAIX expression in MCF-7 cells is 
consistent with a higher activity of FIH-1 in this 
cell line
CAIX protein expression is induced by HIF-1α 
[13, 26]. Results showed that the 3 cell lines express 
very different amounts of CAIX, despite having similar 
levels of HIF-1α (Figure 2). To further analyze why CAIX 
expression varies, additional experiments were performed 
to assess CAIX levels in 20% O2 in the 3 cell lines when 
treated with cobalt chloride (CoCl2), which inhibits prolyl 
hydroxylase domain proteins (PHDs) and prevents the 
degradation of HIF-1α in aerobic conditions. All 3 cell 
lines had similar levels of stabilized HIF-1α when treated 
with CoCl2, with the largest amount of HIF-1α observed 
5h after treatment in nuclear lysates (Figure 4A). However, 
CAIX protein expression again differed between the cell 
lines, with both CoCl2-treated MDA-MB-231 and HBL-
100 cells expressing CAIX, while MCF-7 cells lacked a 
CAIX band in cytoplasmic samples (Figure 4A). These 
results were supported by mRNA analysis, which showed 
significantly higher CAIX mRNA levels in CoCl2-treated 
HBL-100 cells (Figure 4B) compared to un-treated cells. 
These findings suggest that the variation in CAIX proteins 
levels between these cell lines is not due to a disparity in 
HIF-1α expression.
Figure 3: mRNA changes in response to different oxygen conditions. CAIX (A and B), (B) without the HBL-100 data), NHE1 
(C) and V-ATPase subunits ATP6V1A (D) and ATP6V0A4 (E) mRNA levels were analyzed in cells cultured in 20% O2 (control, C), 
0.5% O2 for 24h (acute hypoxia, AH) and 0.5% O2 for 10 weeks (chronic hypoxia, CH). Data expressed as mean ± SEM (n=3). *P≤0.05, 
**P≤0.01, ***P≤0.001 and ****P≤0.0001 (One-way ANOVA followed by Dunnett’s multiple comparison test performed, comparing only 
the values within each cell line).
Oncotarget6www.impactjournals.com/oncotarget
FIH-1 is an oxygen sensor that inhibits HIF-1α 
C-TAD, thus reducing CAIX expression [27]. Membrane 
type-1 matrix metalloproteinase (MMP14) is a protein that 
inhibits FIH-1 [14]. To assess whether FIH-1 and MMP14 
could be responsible for the differences in CAIX expression 
seen between these cell lines, protein levels were evaluated 
in lysates from the 3 cancer cell lines cultured in 0.5% O2 
(Figure 4C). Results showed that MCF-7 cells had the 
highest levels of FIH-1 protein (lower band) and lacked 
MMP14. Both MDA-MB-231 and HBL-100 cells expressed 
slightly lower levels of FIH-1, while also expressing 
MMP14 (Figure 4C). Further analysis demonstrated that 
MCF-7 cells produce comparable levels of MMP14 mRNA 
to the other cell lines examined (Figure 4D). Therefore, 
differences in MMP14 protein levels observed were not due 
to a lack of gene transcription in MCF-7 cells. These results 
suggest that MMP14 and FIH-1 may co-operate to control 
CAIX expression in hypoxia in the cell lines.
To further assess whether FIH-1 was responsible 
for the low CAIX expression levels seen in MCF-7 cells, 
a mixture of 4 pooled siRNAs (Figure 4E, pool) and a 
single siRNA (Figure 4E, 21) targeting FIH-1 were used. 
Both led to reduced levels of FIH-1 in hypoxic MCF-7 
cells compared to the controls, with concurrent increases 
in CAIX expression seen in these same samples (Figure 
4E). Additionally, experiments were conducted using 
this siRNA to inhibit FIH-1 expression in aerobic MCF-
7 cells that had HIF-1α stabilized as a result of CoCl2 
treatment. Aerobic MCF-7 cells treated with both siRNA 
and CoCl2 together showed a strong induction of CAIX, 
while cells treated with siRNA alone did not express 
CAIX (Figure 4F). These data show that increased FIH-
1 activity in MCF-7 cells contributes to the low CAIX 
expression seen in these cells when compared to the 2 
other cell lines.
The effect of S4 on the expression of pH 
regulating proteins
S4 treatment reduced the proliferation of human 
breast cancer cells lines in both aerobic and hypoxic 
conditions, with increased IC50 values observed in acute 
Figure 4: Investigating the cause of the differential expression patterns of CAIX between the cell lines. (A) Nuclear 
levels of HIF-1α and cytoplasmic levels of CAIX in aerobic cells treated with 400 μM cobalt chloride (CoCl2) for 5, 24, 48 and 72h. 
Experiments assessing HIF-1α levels at 5h CoCl2 treatment were carried out separately to the other time points. (B) CAIX mRNA levels in 
aerobic cells (Control, C) and cells treated with 400 μM CoCl2 for 24h. ****P≤0.0001 (Unpaired t test, comparing each CoCl2 sample to 
the 20% O2 sample within each cell line). (C) Cytoplasmic FIH-1 (lower band) and MMP14 expression levels in both aerobic and hypoxic 
conditions in the 3 cell lines. (D) MMP14 mRNA levels in cells cultured in 20% O2 (C), 0.5% O2 for 24h (AH) and 0.5% O2 for 10 weeks 
(CH). (E) siRNA targeting FIH-1 was used to assess whether FIH-1 had any effect on CAIX expression in MCF-7 cells cultured in 0.5% 
O2 conditions. cont, control. m, transfection reagent alone. scr, scrambled siRNA. pool, mixture of 4 siRNAs targeting FIH-1. 21, single 
siRNA targeting FIH-1. (F) FIH-1 and CAIX expression levels in aerobic MCF-7 cells treated with either siRNA against FIH-1 alone, or 
both 400 μM CoCl2 and siRNA together for 24, 48 and 72h.
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hypoxic cells (Figure 1). To examine whether these 
acute hypoxic cells had enhanced expression of the pHi 
regulators in response to CAIX inhibition, thus facilitating 
resistance to this compound, western blots were performed 
on lysates from breast cancer cells treated with S4. Cells 
were cultured in 0.5% O2 for 24h to allow the cells to 
adapt to hypoxic conditions, after which the cells were 
treated with various concentrations of S4 for 24, 48 and 
72h. MCF-7 cells were most sensitive to S4 treatment, 
as higher concentrations of the drug led to a significant 
reduction in CAIX levels at all time points (Figure 5A and 
5B - 100 μM samples were not included at the later time 
points in B since at this concentration the drug affected 
cell number). While 100 μM concentrations of drug did 
reduce CAIX levels in MDA-MB-231 cells, this reduction 
was not found to be significant (Figure 5A). HBL-100 
cells showed no loss of CAIX in response to S4 at any 
drug concentration (Figure 5A). Further, CAIX inhibition 
did not lead to any changes in either NHE1 or V-ATPase 
expression levels in any of the cell lines (Supplementary 
Figure 4).
CAIX and NHE1 are up-regulated in hypoxic 
conditions in 3D
Because 3D multicellular spheroids can more 
accurately replicate many aspects of the tumor 
microenvironment in comparison to cells cultured in 2D, 
including hypoxic and acidic gradients, the expression and 
location of several of the target proteins were investigated 
using this model (Figure 6). Quantitative evaluation 
of target protein expression was carried out, with 
hypoxyprobe used to delineate the normoxic and hypoxic 
areas within spheroids of each of the cancer cell lines. The 
percentage of cells with low, medium and high intensity 
levels of staining within the normoxic and hypoxic regions 
was analysed using Definiens Architect XD 64 Tissue 
Studio 4.1 (Figure 7 and Supplementary Figure 5). As 
in the 2D expression analysis, CAIX levels also differed 
between the cell lines when cultured in 3D. Strong CAIX 
staining was seen within the low % O2 areas of MDA-
MB-231 and HBL-100 spheroids, with significantly 
increased percentages of cells with high intensity levels 
of CAIX staining present in the hypoxic regions of these 
spheroids (Figure 7). Only a small percentage of CAIX 
positive cells were detected within the hypoxic areas of 
MCF-7 spheroids. In contrast, strong induction of NHE1 
protein expression was observed in the hypoxic regions 
of the MCF-7 spheroids, while NHE1 expression levels 
were comparable between the normoxic and hypoxic 
areas of spheroids of the 2 other cancer cell lines (Figure 
7). V-ATPase expression was constant in both aerobic 
and hypoxic areas of spheroids in all of the cell lines 
(results not shown). MMP14 and FIH-1 expression was 
also assessed in 3D. While there were no differences in 
FIH-1 staining observed between the spheroids, MMP14 
expression showed variation. Both MDA-MB-231 and 
HBL-100 spheroids exhibited large amounts of MMP14, 
with extensive plasma membrane staining visible in the 
HBL-100 cells. Cells within MCF-7 spheroids, however, 
had much lower levels of intracellular MMP14 staining. 
Examination of the 3D spheroid models demonstrate that 
while MCF-7 spheroids have little or no CAIX, they do 
express high levels of CAXII. This situation is reversed in 
both HBL-100 and MDA-MB-231 spheroids, where CAIX 
expression is higher, but CAXII is low (Supplementary 
Figure 6A). mRNA analysis of the 3 cell lines cultured 
in 2D in differing O2 conditions agrees with the 3D data, 
showing high CAXII mRNA levels in aerobic MCF-7 cells, 
with much lower levels of CAXII mRNA present in the 
aerobic MDA-MB-231 and HBL-100 cells (Supplementary 
Figure 7). These changes are contrasted with data for the 
reference gene – RPL32, which was unchanged across the 
sample set (Supplementary Figure 7).
S4 treatment reduces the invasion of MDA-
MB-231 cells in 3D
pH plays a central role in tumor cell invasion and 
metastasis [16]. 3D invasion assays were carried out 
Figure 5: CAIX levels in S4-treated hypoxic cancer cells. (A) Whole cell expression levels of CAIX were analyzed in the 3 cancer 
cell lines treated with the CAIX inhibitor S4. The cells were placed into 0.5% O2 conditions for 24h, and were then treated with different 
concentrations of S4 (10/30/100 μM) for 24, 48, and 72h. (B) CAIX expression levels (signal corrected for loading control) in S4-treated 
hypoxic MCF-7 cells. Data expressed as mean ± SEM (n=3). *P≤0.05, **P≤0.01 (One-way ANOVA followed by Dunnett’s multiple 
comparison test performed, comparing only the values within each time point).
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Figure 6: 3D target protein expression in multicellular tumor spheroids. 3D expression analysis was carried out in the MCF-
7, MDA-MB-231 and HBL-100 cell lines using multicellular tumor spheroids. The spheroids were cultured in spinner flasks for 1 week 
before fixation. Hypoxyprobe was used to examine the formation of hypoxic areas within the spheroids. NHE1, CAIX, MMP14 and FIH-1 
expression was also analyzed. Incubation for an hour with PBS instead of primary antibody acted as a control.
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Figure 7: Quantitative analysis of CAIX and NHE1 protein expression levels in multicellular tumor spheroids. 
Quantitative evaluation of CAIX and NHE1 protein expression levels within the normoxic and hypoxic regions of spheroids produced from 
MCF-7, MDA-MB-231 and HBL-100 cancer cell lines was performed using Definiens Architect XD 64 Tissue Studio 4.1. The percentage 
of cells exhibiting low, medium and high intensity levels of staining was calculated. Data expressed as mean ± SEM (n= at least 3 for each 
cell line). *P≤0.05, **P≤0.01, *** P ≤ 0.001, **** P ≤ 0.0001 (Unpaired t-tests performed).
to compare the effects of CAIX, NHE1 and V-ATPase 
inhibition on cancer cell invasion from MDA-MB-231 
and HBL-100 spheroids embedded in collagen type 1. 
MCF-7 spheroids were not used, as they do not invade in 
3D culture. 100 μM S4 significantly reduced the invasion 
of cells from MDA-MB-231 spheroids, compared to un-
treated spheroids, in both 20% O2 (Figure 8A) and 0.5% 
O2 cell culture conditions (Figure 8D). However the drug 
had no significant effect on the invasion of cells from 
HBL-100 spheroids in either aerobic or hypoxic conditions 
(Supplementary Figure 8). Drugs targeting NHE1 and 
V-ATPase had no inhibitory effect on the invasion of cells 
from either MDA-MB-231 or HBL-100 spheroids in either 
20% O2 or 0.5% O2 conditions (Supplementary Figure 9 
and 10). These results suggest that of these pH regulators, 
CAIX expression may be the most important in regard to 
facilitating invasion.
CAIX and NHE1 inhibitors combine effectively 
with irradiation
Hypoxic cancer cells are relatively resistant to 
radiotherapy [17]. To investigate if drugs targeting 
pH regulatory molecules could increase the effects of 
irradiation, 3D clonogenic assays were performed with 
MDA-MB-231 spheroids. Figure 9A shows the response 
of cells from MDA-MB-231 spheroids to a range of 
irradiation doses. The low dose of 0.5 Gy was used in 
combination experiments to help observe additive or 
synergistic effects. The CAIX inhibitor S4 (Supplementary 
Figure 11A) and the V-ATPase inhibitor bafilomycin A1 
(Supplementary Figure 11B) showed no combinatorial 
effects. However, studies with the more potent CAIX 
inhibitor FC9403A [22] (Figure 9B), and the NHE1 
inhibitor DMA (Figure 9C), led to a significantly lower 
colony number when combined with irradiation compared 
against either irradiation or drug treatment alone.
Proteomic-mass-spectrometric analysis was carried 
out to analyze the possible mechanisms through which 
FC9403A was combining with irradiation in MDA-
MB-231 cells. Overall, 5414 proteins were detected in 
this preliminary analysis. Proteins identified as being 
up-regulated or down-regulated in the different treatment 
groups are shown in Figure 10A, with proteins identified 
as having key biological functions indicated in Figure 10B 
(see Supplementary Figure 11C for the full list of proteins 
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present in Figure 10B). The HIF-1α inhibitor OS9, the cell 
cycle regulator CCNH, and the anti-apoptotic BCL2L1 
are examples of proteins that were significantly down-
regulated in the cells that received a combination of both 
irradiation and drug. The pro-apoptotic molecules PTGES 
and BNIP3, the DNA repair proteins KIN and KIAA0101, 
the transcription factor JUNB, and the neural development 
signaling molecule NOTCH3 were all up-regulated in the 
combined treatment group.
DISCUSSION
This study compared the therapeutic effect 
of targeting CAIX, NHE1 and V-ATPase in breast 
cancer, assessing the effects of inhibition in different 
O2 conditions using both 2D and 3D culture models. 
Inhibitors of each of the 3 targets demonstrated anti-
proliferative effects in breast cancer cell lines (Figure 1 
and Supplementary Figure 2), in agreement with other 
studies in breast and other cancer cell types [28–30]. The 
V-ATPase inhibitor bafilomycin A1 had the most potent 
effects on proliferation, reflecting the diverse biological 
roles performed by V-ATPase that are crucial for cell 
function [31].
Higher IC50 values for the inhibitors in acute hypoxia 
suggested increased resistance to the compounds in these 
conditions. These results seem counter-intuitive since it 
would be predicted that hypoxic cells, which are more 
reliant on glycolysis, would show amplified sensitivity to 
inhibition of pH regulating proteins. Resistance could be 
enhanced by increased target expression generated as cells 
adapt to acute hypoxia, meaning that higher concentrations 
of drug are needed in the hypoxic cells to induce the same 
effect seen in the aerobic cells. However, NHE1 showed 
little change in expression other than in MCF-7 cells in 
chronic hypoxia, while V-ATPase protein expression was 
unaffected by differing oxygen concentrations (Figure 
2). Hypoxia can increase both CAIX and NHE1 activity, 
which may be a further factor in drug resistance [32–34]. 
Conversely, chronic hypoxic MCF-7 and MDA-MB-231 
cells displayed similar IC50 values for the CAIX inhibitor 
to cells in aerobic conditions, suggesting that such 
resistance may be reversible.
Previous studies examining CAIX, NHE1 or 
V-ATPase expression in hypoxia produced disparate results 
[33–36]. In this study, both NHE1 protein and mRNA 
levels remained fairly constant in each of the cell lines 
under differing oxygen conditions, except for increased 
protein in chronically hypoxic MCF-7 cells (Figure 2), and 
a decrease in mRNA levels in HBL-100 cells cultured in 
chronic hypoxic conditions (Figure 3C). While no positive 
correlation between hypoxia and V-ATPase regulation has 
been shown to date [37], the distribution of V-ATPase 
within cells has been shown to be cell type dependent. 
For example, V-ATPase is present both intracellularly and 
on the cell surface in highly metastatic MDA-MB-231 
Figure 8: The effect of the CAIX inhibitor S4 on 3D cancer cell invasion from MDA-MB-231 spheroids in 20% O2 and 
0.5% O2 conditions. MDA-MB-231 spheroids were produced in spinner flasks, placed into collagen type 1 and left to invade for 48h 
in either 20% O2 or 0.5% O2 conditions. Invasion was measured using the image processing package FIJI. Graphs show the % invasion in 
20% O2 (A) and 0.5% O2 (D) conditions. Data expressed as mean ± SD (n=4). **P≤0.01, ****P≤0.0001 (One-way ANOVA followed by 
Dunnett’s multiple comparison test). Representative images of control spheroids present in collage type 1 in 20% O2 conditions for 0h (B) 
and 48h (C), along with spheroids present in 0.5% O2 conditions for 0h (E) and 48h (F), are shown.
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cells, with lower levels found on the plasma membrane 
in non-metastatic MCF-7 cells [38]. V-ATPase subunit 
composition governs V-ATPase location within the cell. 
The ATP6V0A3 and ATP6V0A4 subunits are thought to 
target V-ATPase to the plasma membrane [25], where the 
protein regulates pHi and contributes to invasion through 
the acidification of the extracellular environment. mRNA 
analysis of the ATP6V0A3 subunit showed that there 
was no significant differences in expression levels in 
hypoxic conditions (Supplementary Figure 3); however, 
significantly higher levels of the ATP6V0A4 subunit were 
expressed in chronically hypoxic MDA-MB-231 cells 
compared to cells in 20% O2 (Figure 3E), suggesting that 
chronic hypoxia may increase the levels of V-ATPase 
targeted to the plasma membrane in MDA-MB-231 cells. 
This would further account for the increased migratory 
capacity of this cell line in hypoxia [22].
HIF-1α and HIF-2α are both key mediators of the 
response of hypoxic cancer cells to low O2 conditions; 
HIF-1α responds to acute hypoxic conditions, while 
HIF-2α accumulates over time [39, 40]. These temporal 
responses were not observed in the cell lines that did 
express HIF-2α. In both MDA-MB-231 and HBL-100 
cells, HIF-2α levels decreased in chronic hypoxic cells 
compared to acute hypoxic cells, while HIF-1α levels 
remained constant (Figure 2).
HIF-1α levels increased in hypoxic conditions in all 
cell lines examined. However, CAIX, which is induced by 
HIF-1 [13, 26], showed variable expression between cell 
lines and was only markedly up-regulated in MCF-7 cells 
after exposure to chronic hypoxia, implying that further 
mechanisms must be involved (Figure 2). While CAIX is 
a HIF-inducible gene, studies have shown that CAIX is 
only expressed when HIF-1α retains C-TAD activity (that 
is, when the co-activator p300/CBP is bound to HIF-1α) 
[27, 41]. HIF-1α gene expression can be inhibited by FIH-
1, which hydroxylates the C-TAD of HIF-1α and prevents 
the binding of co-activators to HIF-1α [11]. MMP14 is 
a protein that can inhibit FIH-1 [14]. The active form 
of MMP14 is present on the cell surface as a 57 kDa 
transmembrane protein. Autocatalytic cleavage can 
generate a membrane-tethered inactive product (44 kDa) 
and a soluble catalytically inactive fragment (18 kDa) 
[42]. Westerns were performed looking at both FIH-1 
and MMP14 levels in the 3 cell lines to assess whether 
these proteins might explain the differing CAIX results 
observed.
MCF-7 cells expressed the highest levels of FIH-1, 
but lacked active MMP14 (57 kDa) (Figure 4C). Therefore 
in acute hypoxic MCF-7 cells, FIH-1 can hydroxylate the 
C-TAD of HIF-1α, blocking the binding of p300/CBP 
and leading to only partial activation of HIF signaling. 
Although FIH-1 is still active at lower O2 percentages, 
severely hypoxic conditions have been shown to reduce 
activity [12], which may explain why MCF-7 cells can 
express CAIX under chronically hypoxic conditions 
(Figure 2). Conversely, MDA-MB-231 and HBL-100 
cells expressed lower levels of FIH-1 but high levels of 
active MMP14 (Figure 4C). Therefore in acute hypoxic 
MDA-MB-231 and HBL-100 cells, MMP14 may inhibit 
FIH-1, enabling p300/CBP to bind to HIF-1α, leading to 
the expression of C-TAD sensitive genes such as CAIX. 
Prior reports have demonstrated that FIH-1 suppression 
through siRNA treatment leads to increased CAIX protein 
levels in in aerobic and acute hypoxic conditions in 
hepatoma and osteosarcoma cell lines [43]. In agreement 
with these results, siRNA targeting FIH-1 was seen to 
lead to increased levels of CAIX in both acute hypoxic 
Figure 9: Clonogenic assays assessing the combination of drugs targeting CAIX and NHE1 with irradiation. (A) MDA-
MB-231 spheroids were treated with a range of radiation doses to see which dose would be optimal to assess any additive/synergistic drug 
effects. Data expressed as mean ± SD (n=3). *** P ≤ 0.001, **** P ≤ 0.0001 (One-way ANOVA followed by Dunnett's multiple comparison 
test). (B) 3D clonogenic assay performed with MDA-MB-231 spheroids treated with the CAIX inhibitor FC9403A. Data expressed as mean 
± SD (n=8). *P≤0.05, ***P≤0.001 (Kruskal-Wallis test performed). (C) 3D clonogenic assay performed with MDA-MB-231 spheroids 
treated with the NHE1 inhibitor DMA. Data expressed as mean ± SD (n=9). *P≤0.05, ****P≤0.0001 (One-way ANOVA followed by 
Tukey’s multiple comparison test).
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Figure 10: Proteomic-mass-spectrometric analysis assessing the mechanism of irradiation and CAIX inhibition 
combination. Proteomic-mass spectrometric analysis was carried out on MDA-MB-231 cells treated with 0.5 Gy, 3 μM FC9403A, or a 
combination of both irradiation and CAIX inhibitor. Untreated MDA-MB-231 cells acted as the control. (A) Proteins identified as being 
either significantly up-regulated or down-regulated in the different treatment groups, identified using the Rank product test. (B) Protein 
changes detected within each of the different treatment groups, with examples of proteins with important biological functions highlighted.
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and CoCl2-treated MCF-7 cells (Figure 4E and 4F). 
These observations are consistent with FIH-1 and loss of 
MMP14 being involved in the low CAIX expression levels 
seen in MCF-7 cells (illustrated in Figure 11). However, 
further work is required to confirm the role of MMP14 in 
the control of CAIX expression within these breast cancer 
cell lines.
Studies have shown that HIF-2α modulates MMP14 
expression [44]. However, MMP14 protein was present 
in both MDA-MB-231 and HBL-100 cells in aerobic 
conditions when HIF-2α was absent, and although HIF-
2α levels increased in hypoxic MDA-MB-231 and HBL-
100 cells, MMP14 expression did not. All the cell lines 
transcribed similar levels of MMP14 mRNA (Figure 4D), 
suggesting that differences in gene expression cannot 
explain the lack of active MMP14 in MCF-7 cells. It is 
possible that these cells either do not translate the MMP14 
protein, or do so in amounts that are below detectable 
levels. Otherwise, the MCF-7 cells may translate similar 
levels of MMP14 to the other 2 cell lines, but the protein 
may be rapidly broken down in 2D culture in MCF-7 cells.
Expression of the target molecules was also assessed 
in more physiological 3D tumor spheroid models. These 
studies demonstrated results similar to those observed in 
2D culture. CAIX was induced in the hypoxic areas of 
HBL-100 spheroids, but little or no CAIX expression was 
apparent in the hypoxyprobe-positive areas of MCF-7 
spheroids (Figures 6 and 7). CAIX expression was also 
evident within the hypoxic areas of the MDA-MB-231 
spheroids, with some staining also present in cells outside 
the hypoxyprobe positive region. Because FIH-1 activity 
can be reduced under severely hypoxic conditions [12], 
and CAIX expression occurred in chronic hypoxic MCF-
7 cells in 2D cultures, MCF-7 spheroids were further 
assessed for CAIX expression after 2 and 3 weeks of 
spheroid growth. However, no hypoxic cells were present 
in the 2/3 week MCF-7 spheroids (Supplementary Figure 
12), preventing such analysis.
To understand whether similar processes governed 
the expression of CAIX in the spheroids, MMP14 and 
FIH-1 expression was analyzed. No differences in FIH-1 
staining were observed between the different spheroids, 
but MMP14 expression did vary (Figure 6). Both MDA-
MB-231 and HBL-100 spheroids exhibited large amounts 
of plasma membrane MMP14 staining, while only light 
intracellular staining was observed in MCF-7 spheroids. 
Because 2D analysis showed that MCF-7 cells do not 
express active 57kDa MMP14, we believe this staining 
may indicate the presence of the inactive 18kDa fragment 
of MMP14 produced after autocatalysis; firstly, because 
the antibody used binds to the extracellular domain of the 
protein and secondly, because the lack of CAIX staining in 
the MCF-7 spheroids suggests that FIH-1 is not inhibited 
and therefore any MMP14 present is possibly inactive. 
Further investigation into why both MDA-MB-231 and 
HBL-100 cells retain the active form of MMP14, while 
the MCF-7 cells do not, is merited.
The low expression of CAIX in both 2D and 3D 
MCF-7 models raises the question of why inhibitors 
such as S4 can inhibit proliferation in these cells. S4 has 
been shown to have high affinity for both the IX and XII 
isoforms of the carbonic anhydrase enzymes, with a KI 
Figure 11: Regulation of HIF signaling in hypoxia and the consequences for CAIX expression in the 3 breast cancer 
cell lines. (A) In acute hypoxic MCF-7 cells, FIH-1 has retained its activity. FIH-1 hydroxylates the C-TAD of HIF-1α, preventing co-
activator binding. HIFβ binds to the HIF-1α that has been stabilized in hypoxia, resulting in partial HIF signaling and only a small amount 
of CAIX expression. (B) Severe hypoxia inactivates FIH-1, enabling the co-activator p300/CBP to bind to the C-TAD of HIF-1α, resulting 
in full HIF signalling and CAIX expression in chronic hypoxic MCF-7 cells. (C) FIH-1 activity may be reduced by MMP14 in acute 
hypoxic MDA-MB-231 and HBL-100 cells, enabling p300/CBP binding and full HIF signalling, leading to CAIX expression in acute 
hypoxic conditions in these cell lines. (D) Both severe hypoxia and MMP14 may act in combination to inactivate FIH-1 in chronic hypoxic 
MDA-MB-231 and HBL-100 cells, resulting in high levels of CAIX expression.
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reported at 7 nM for CAIX and 2 nM for CAXII [19, 45]. 
Furthermore, CAXII is also a hypoxia-inducible protein 
[32]. Examination of the 3D spheroid models demonstrate 
that while MCF-7 spheroids have little or no CAIX, 
they do express high levels of CAXII. This situation is 
reversed in both HBL-100 and MDA-MB-231 spheroids 
where CAIX expression is higher, but CAXII is low 
(Supplementary Figure 6). Therefore S4 is most probably 
inhibiting the CAXII isoform of carbonic anhydrase in 
MCF-7 cells, leading to the anti-proliferative effects. 
mRNA analysis of the 3 cell lines cultured in 2D in 
differing O2 conditions agrees with the 3D data, showing 
high CAXII mRNA levels in aerobic MCF-7 cells, with 
much lower levels of CAXII mRNA present in the aerobic 
MDA-MB-231 and HBL-100 cells (Supplementary 
Figure 7). Interestingly, while the 2D protein (Figure 2) 
and mRNA (Figure 3) data show CAIX levels increasing 
in the hypoxic MCF-7 cells, the mRNA (Supplementary 
Figure 7) and protein (Supplementary Figure 6A and 
6B) data show that CAXII levels decrease in hypoxic 
MCF-7 cells compared to aerobic cells, suggesting that 
CAXII expression may be responding to the increased 
CAIX expression in hypoxic conditions. Other studies 
have also shown a similar interaction between CAIX 
and CAXII expression [32, 46], as well as for CAIX and 
CAII [47]. Together, these results indicate that carbonic 
anhydrase isoform expression may depend on some form 
of interaction between the different isoforms.
3D invasion assays highlighted the ability of 
CAIX inhibitors to hinder the invasion of MDA-MB-231 
spheroids, with 100 μM of S4 significantly reducing the 
amount of invasion in both aerobic and hypoxic conditions 
(Figure 8A and 8D). Because both active MMP14 and 
CAIX have been linked to invasion [22, 42], and MMP14 
is connected to the expression of CAIX, our results may 
explain why MCF-7 cells and spheroids lack invasive 
capabilities. Although CAIX inhibition did not have any 
significant effects on the invasion of HBL-100 spheroids, 
further experiments assessing the effects of combining 
both CAIX and MMP14 inhibition may prove more 
effective.
Hypoxic cancer cells can tolerate a 2-3 times higher 
dose of irradiation than aerobic cells for the same effect 
[48]. Therefore, methods to improve the effectiveness of 
radiotherapy in hypoxic tumors are required. Radiotherapy 
in combination with chemotherapy has improved tumor 
response and patient survival, but the restricted specificity 
of current chemotherapy drugs used in combination can 
cause tissue toxicity [49]. Using inhibitors targeting 
proteins that are selectively expressed/activated in 
hypoxic cancer cells, such as the pH regulating proteins, 
has the potential to improve the treatment of patients. 
3D clonogenic assays conducted with MDA-MB-231 
spheroids demonstrated that the CAIX inhibitor FC9403A 
(Figure 9B) and the NHE1 inhibitor DMA (Figure 
9C), in combination with irradiation, decreased colony 
formation in comparison to either treatment alone. 
Irradiation requires oxygen for effective therapy, therefore 
hypoxic cells at the center of the spheroids should show 
increased resistance to the effects of radiotherapy. While 
FC9403A produced a beneficial effect in combination with 
irradiation, S4 failed to do so (Supplementary Figure 11). 
The reasons for this are unclear, but we have previously 
observed that FC9403A was a more potent anti-invasive 
agent than S4 [22].
Proteomic-mass-spectrometric analysis was 
performed to investigate the possible mechanism of 
FC9403A combination with irradiation (Figure 10), with 
proteins identified as having key biological functions 
identified in this preliminary analysis (Figure 10B). The 
induction of apoptosis is one way in which radiotherapy 
achieves its therapeutic effect [50]. Cells that were 
treated with a combination of irradiation and FC9403A 
were shown to have higher levels of PTGES and BNIP3, 
both of which have been linked to the induction of 
apoptosis [51, 52] and lower levels of BCL2L1, which 
has been reported to have anti-apoptotic functions [53]. 
The induction of apoptosis after treatment with CAIX 
inhibitors has been shown in previous studies [22]. 
Therefore, one potential mechanism through which CAIX 
inhibition may be combining with irradiation could be 
through the stimulation of apoptotic cell death. Aside 
from apoptosis, radiotherapy can also lead to mitotic cell 
death as a result of the induction of DNA damage. DNA 
damage repair within cancer cells is key to deciding the 
response to irradiation treatment [54]. The combination 
of irradiation and FC9403A led to increased levels of KIN 
and HIAA0101, both of which have been linked to DNA 
repair [55, 56] suggesting that combination treatment may 
be increasing the extent of DNA damage induced.
Although previous studies support the benefits of 
combining irradiation with a molecular targeted agent, 
there remains a severe lack of clinical trials that test this 
strategy. The early evaluation of novel molecular targeted 
agents in combination with irradiation, as shown in this 
study, could lead to the identification of drugs that work 
effectively with irradiation, and improve patient survival 
[49]. Inhibitors targeting the pH regulating proteins that 
are selectively up-regulated/activated in hypoxic cancer 
cells, with their ability to also affect the invasion of 
cancer cells, could prove to be such agents. Of the three 
pH regulatory molecules, CAIX represents the target with 
the most promise, with one CAIX inhibitor (SLC-0111) 
currently in Phase I clinical trials.
SUMMARY
This study compared the therapeutic effect of 
targeting CAIX, NHE1 and V-ATPase in both 2D and 3D 
breast cancer models. Inhibitors targeting these proteins 
were shown to have anti-proliferative effects on breast 
cancer cell lines. Expression analysis highlighted the 
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up-regulation of two of the targets, CAIX and NHE1, in 
hypoxic conditions in both 2D and 3D, with the varying 
CAIX levels between the cell lines a result of differential 
FIH-1 activity, possibly resulting from varying MMP14 
expression. The potential of pH inhibition as a possible 
treatment for cancer patients was further highlighted in the 
ability of drugs targeting CAIX to inhibit the invasion of 
cancer cells in 3D, while both CAIX and NHE1 inhibitors 
were shown to combine with irradiation in clonogenic 
assays. Proteomic-mass-spectrometric analysis indicated 
that CAIX inhibition might be combining with irradiation 
through stimulating apoptotic cell death.
MATERIALS AND METHODS
All materials were obtained from sigma-aldrich 
unless otherwise stated
Cell culture
Breast cancer cell lines MCF-7, MDA-MB-231, and 
HBL-100 were cultured in DMEM (Gibco) supplemented 
with 10% FCS (fetal calf serum, PAA), 50 U ml-1 penicillin 
and 50 mg ml-1 streptomycin. Cell lines were obtained either 
from ATCC or PHE (Porton Down, Salisbury, UK) and 
were authenticated by STR profiling. All aerobic cells were 
incubated at 37°C with 5% CO2 in a humidified incubator. 
Hypoxic cells were cultured in a hypoxic chamber (Whitley 
H35 hypoxystation) and maintained at either 0.5%, 2% or 
7% O2 and 5% CO2, balanced with N2 at 37°C.
Pharmacological inhibitors
The V-ATPase inhibitor bafilomycin A1 was 
obtained from Wako Pure Chemical Industries, Ltd. The 
CAIX inhibitors S4 and FC9403A were synthesized by 
Fabrizio Carta and Claudiu Supuran.
siRNA treatment
5 – 15 x 104 MCF-7 cells were cultured for aerobic/
hypoxic experiments in DMEM containing 10% FCS, 
with hypoxic cells cultured at 0.5% O2. After 24h, cells 
were transfected using Dharmafect transfection reagent 
(Dharmacon, T-2001-03), and a final siRNA concentration 
of 50 nM was used (pool [L-004073-03], single [L-
004073-21], and scrambled [D-01810-01], Dharmacon). 
After 48h, the transfection reagents were replaced with 
DMEM + 10% FCS, and cells lysed 72h later. In aerobic 
MCF-7 CoCl2 experiments, CoCl2 was added at 24h 
intervals during this 72h period.
Protein isolation
Whole cell lysates of aerobic or hypoxic cells were 
obtained after washing cultures with PBS and treating with 
lysis buffer (50 mM Tris pH 7.5, 5 mM EGTA pH 8.5 and 
150 mM NaCl) containing one complete protease inhibitor 
tablet (Roche), 100 μl phosphatase inhibitor cocktail 2, 
100 μl phosphatase inhibitor cocktail 3, 50 μl aprotinin 
and 1% Triton X-100. The samples were centrifuged at 
13,000 g; all procedures were performed at 4°C.
Nuclear/cytoplasmic lysates were acquired by 
washing cells with PBS and spinning at 13,000 rpm for 1 
min. The pellet was re-suspended in 400 μl of lysis buffer 
(10 mM HEPES pH7.8, 10 mM KCl, 2mM MgCl2, 0.1mM 
EDTA) for 15min before adding 15μl of a IGEPAL CA-
630 solution. After vortexing, samples were spun at 13,000 
rpm for 1 min. The supernatant contains the cytoplasmic 
fraction. 50 μl of solution containing 50 mM HEPES 
pH 7.8, 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA and 
10% sterile glycerol (VWR) was added and samples were 
rotated for 20 min at 4°C. Samples were centrifuged at 
13,000 rpm for 5 min. The supernatant contained the 
nuclear fraction. All lysates were stored at -80°C. Protein 
concentration was determined using a BCA assay.
Western blot analysis
Separated proteins were transferred onto an 
Immobilon-P transfer membrane (Millipore), which was 
blocked using a solution containing 50% PBS and 50% 
Odyssey Blocking Buffer (Li-Cor), before incubating 
overnight at 4°C with primary antibodies (ATP6V1A 
polyclonal antibody [Abnova, H00000523-A01, 1:2000], 
carbonic anhydrase IX antibody clone m75 [Bioscience 
Slovakia, 1:6000], purified mouse anti-NHE [BD 
Biosciences, 611774, 1:1000], HIF-1α [BD Biosciences, 
610958, 1:250], HIF-2α [Novus Biologicals, NB100-
122, 1:1000], Factor inhibiting HIF-1α antibody [Novus 
Biologicals, NB100-428, 1:1000], anti-MMP14 antibody 
[Abcam, ab51074, 1:4000]; anti-α tubulin [Abcam, 
ab7291, 1:10000], anti-β actin [Abcam, ab8227, 1:8000], 
and anti-Lamin B1 [Abcam, ab133741, 1:2500]. Signals 
were detected using IRDye 800CW [Li-Cor, 926-32210, 
1:10000] and IRDye 680LT [Li-Cor, 926-68021, 1:10000] 
and a Li-Cor Odyssey Imager.
SRB assay
Cells were seeded into 96-well plates and incubated 
overnight in 20% O2. Acute hypoxic cells were placed into 
the hypoxystation and cultured in 0.5% O2 for 24h (the 
chronic hypoxic cells were kept in 0.5% O2 at all times). 
Cells were drug-treated after 24h, and cultures fixed 
between 72-120h later by addition of 50 μl cold 25% TCA 
(trichloracetic acid) solution per well at 4°C for 1 h. Plates 
were washed with H2O. When dry, 50 μl SRB dye solution 
was added per well for 30 min. Plates were washed 4 times 
with 1% glacial acetic acid (VWR) and when dry, 150 μl 
Tris buffer solution was added per well. After 1 h, plates 
were read at 540 nM on a plate reader (BP 800 Biohit). IC50 
values were calculated using the Excel package Fit Designer.
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Formation of the MTSs
Cell lines were grown as conventional 2D monolayer 
cultures to approximately 80% confluency before being 
trypsinized to yield single cell suspensions. These were 
transferred to spinner flasks (VWR) inside a humidified 
incubator of 5% CO2 at 37°C. Spheroids used in IHC were 
treated with pimonidazole HCI (Hypoxyprobe, HP1-100) 
for 1 h before fixation.
Immunohistochemistry (IHC)
Formalin-fixed spheroids were embedded, cut 
and mounted on glass slides. The slides were de-
paraffinized and antigens retrieved using a sodium 
citrate solution (0.1M citric acid, 0.1M NaCitrate). 
Endogenous peroxidase activity was inhibited with 
H2O2 solution (Dako), and non-specific background 
staining was blocked using Total Protein Block (Dako, 
X0909). Primary antibodies were incubated for 1h at 
room temperature (hypoxyprobe antibody [hypoxyprobe, 
HP1-100, 1:8000], carbonic anhydrase IX antibody clone 
m75 [Bioscience Slovakia, 1:1000], purified mouse anti-
NHE [BD Biosciences, 611774, 1:400], FIH-1/HIF-AN 
antibody [Novus Biologicals, NB100-428, 1:1000], anti-
MMP14 antibody [Abcam, ab51074, 1:250]). After 1h, 1 
drop of envision labeled polymer (Dako, K4001/K4003) 
was added, and the slides were left for 30 min. DAB and 
substrate buffer (1:50) (Dako, K3466) were added to 
each section and slides counterstained in hematoxylin. 
Images of the slides were taken using the Nanozoomer 
XR (Hamamatsu). Quantitative evaluation of protein 
expression was performed with Definiens Architect XD 
64 Tissue Studio 4.1.
3D invasion assays with MTSs
Cell matrix type 1-A (Alphalabs), 1:1000 acetic 
acid, 0.22 M NaOH, FCS and 10x DMEM were mixed on 
ice at concentrations of 25%, 45%, 10%, 10%, and 10% 
respectively to create a collagen gel. A single spheroid 
was taken up along with some of the collagen gel into a 
0.5 ml volume, and placed into a well of a 24-well plate. 
Cultures were incubated for 1h to allow polymerization. 
A 200 μl pipette tip was used to loosen the collagen plug 
and 0.5 ml DMEM +/- drug was added. Photographs of 
MDA-MB-231 spheroids were taken at 0h and 48h, while 
HBL-100 were imaged at 0h and 72h, using phase contrast 
microscopy (Axiovert S100) (x5 objective). Invasion was 
measured using the image processing package FIJI [57].
Irradiation experiments
Clonogenic assays were performed with MDA-
MB-231 spheroids irradiated at 0.5 Gy using a Faxitron 
RX-650. After irradiation, the spheroids were dissociated 
and cells counted before re-plating 1 x 103 in media with or 
without drug. The plates were left for a week, after which the 
cells were fixed and stained with 1, 9-dimethyl-methylene 
blue zinc chloride double salt. Only colonies of 50 cells or 
over were counted. Proteomic-mass spectrometric analysis 
was also performed with lysates that were acquired 24h after 
the initial treatment. The samples were subjected to FASP 
(Filter aided sample preparation) [58] and the resulting 
peptides cleaned up on stage tips [59] before analysis on 
a Thermo RSLC 3000 Nano with a home-packed 10 cm x 
75 um, 1.8 um C18 particle, home-pulled packed emitter, 
coupled to QExactive Plus. 15 mins loading at 0.4 μL/
min, 2% organic (ACN; 0.05% acetic acid) was followed 
by a 120 min linear gradient to 50% organic, and 80% 
wash. 2% equilibration completed the method. MS1 scan 
range was 300-1650, AGC 3x106 and max ion time 60 
ms. Fragmentation was data dependent, with AGC 2x104, 
max ion time 250 ms, loop 12, top 12, and normalized 
collision energy of 26. Data were processed in MaxQuant 
version 1.5.3.17 [60] with uniprot human reference 
proteome (UP000005640_9606, release 2015_12), and 
normalized LFQ were generated with match-between-runs 
enabled. Initial analysis and QC was performed with R 
version 3.2.3 (2015-12-10) [61]. Raw data are available at 
the ProteomeXchange Consortium via the PRIDE partner 
repository with the dataset identifier PXD005706.
mRNA expression studies
Pellets, comprising approximately 3x106 cells, 
from cell lines (MCF-7, MDA-MB-231 and HBL-100), 
grown under the experimental conditions specified above, 
were collected by trypsinisation and stored at -70°C. 
RNA was extracted using the RNeasy Mini kit (Qiagen) 
and quantity and quality was verified on a Bioanalyser 
2100 with RNA 6000 Nano Kit (Agilent) and Nanodrop 
2000c (Thermo Scientific). RNA was reverse transcribed, 
amplified and labelled using the Illumina TotalPrep RNA 
Amplification kit (Ambion) and hybridised to whole 
genome HumanHT-12 v4 Illumina BeadChips. Arrays 
were scanned using an Illumina iScan. All kits were used 
according to the manufacturer’s standard protocols. Raw 
gene expression files were filtered using the Illumina probe 
detection P-value then log2-transformed and quantile-
normalised using the lumi Bioconductor package.
Statistical analysis
ANOVAs followed by Dunnett’s multiple 
comparison tests were performed to assess whether 
significant results were obtained in the drug treatment 
westerns and the invasion assays. Kruskal-Wallis tests 
and one-way ANOVAs followed by Dunnett’s and 
Tukey’s multiple comparison tests were performed for the 
clonogenic assays. Differentially expressed proteins were 
distinguished in the proteomic-mass-spectrometry analysis 
through rank product testing. GraphPad Prism 6 was used 
to perform the analyses.
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